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The use of 𝜷-lactamase inhibitors in combination with 𝜷-lactam antibiotics is
an emerging area in drug discovery. This strategy allows the restoration of the
therapeutic efficacy of these antibiotics in clinical use against multiresistant
bacteria. These pathogens are drug resistant because they express
𝜷-lactamase enzymes, which prevent the antibiotic therapeutic action by
catalyzing the hydrolysis of the 𝜷-lactam ring. These enzymes are quite
diverse in both their structural architecture and hydrolytic capability, as well
as in the mechanism of action. The ever-increasing emergence of pathogens
that are capable of coproducing different types of 𝜷-lactamases has triggered
the search for ultrabroad-spectrum inhibitors capable of deactivating both
serine- and metallo-𝜷-lactamases. A recent breakthrough in this long-pursued
and unmet need is the discovery of bicyclic boronate inhibitors, specifically
taniborbactam, VNRX-7145, and QPX7728, which are currently under clinical
development in combination with cefepime, ceftibuten, and QPX2014,
respectively. The present article highlights the therapeutic potential of these
inhibitors and their spectrum of efficacy is compared with those of other
𝜷-lactam/𝜷-lactamase inhibitor combinations recently approved by the food
and drug administration. The molecular basis of the ultrabroad-
spectrum of activity of boron-based inhibitors is also discussed, on the basis
of the available crystal structures and the results of computational studies.
1. Resistance Breakers: The Right Antibiotic
Partner for Reversing Antibiotic Drug Resistance
The ability of antibiotics to cure bacterial infections is nowa-
days in serious danger due to the emergence and dissemination
worldwide of multidrug-resistant bacteria.[1–3] These pathogens
have evolved by developing highly sophisticated, and sometimes
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unpredictable, mechanisms to avoid the ac-
tion of antibiotics.[4] The increasing im-
pact of these deadly pathogens in health-
care systems is worrisome, since in these
cases the compromised immune system of
patients facilitates the pathogenicity. Resis-
tance to antibiotics is reaching such dan-
gerous levels that the World Health Or-
ganization (WHO) estimates that by 2050
deaths from antibiotic resistance will ex-
ceed those caused by cancer, and around
ten million people could die every year be-
cause of this problem.[5] Despite this alarm-
ing estimate, the number of new classes
of antibiotics approved in the last 50 years,
either by disabling unexploited bacterial tar-
gets or with a new mechanism of action,
is rather low.[6] Thus, most of the antibac-
terial drugs in the pipeline involve chem-
ical modifications of earlier discoveries to
make them more efficient against resistant
bacteria.[7] The limited profit margin of the
anti-infective therapies (short-term treat-
ments) hinders the recovery of the huge
investment costs required to identify re-
search niches and develop small molecules
that target them, and this seems to be themain reasonwhy antibi-
otic discovery programs have been discontinued by the big phar-
maceutical companies. In fact, most of the new compounds in
this area are being developed by small biotechnology companies.
Another drawback is the policy ofminimizing the use of the latest
generation antibiotics because it goes against the basic principle
of any company, i.e., the need to sell drugs tomakemoney and be
profitable. A reimbursement reform is also needed tomake phar-
maceutical companies more attractive businesses for investors.
A review of the clinical antibacterial drug pipeline reveals that
current research efforts are focused on restoring the efficacy of
antibiotics in clinical use, which have proven to be safe and effec-
tive over the years. This successful and growing area of investiga-
tion involves the administration of the antibiotic in combination
with a compound that either blocks a certain bacterial resistance
mechanism or potentiates the action of the drug by facilitating
its permeabilization into the bacterium. These compounds are
known as “resistance breakers,” “antibiotic adjuvants” or “an-
tibiotic potentiators,” and they usually lack relevant bactericidal
activity in the dose that is administered.[8–20] Among them, 𝛽-
lactamase inhibitors are the most prominent as they have proven
to be the most successful compounds in restoring the efficacy of
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Figure 1. A) Enzymatic inactivation of carbapenems. B) Bacterial pathogens of critical priority according to the WHO. C) Most relevant bicyclic boronate
inhibitors under clinical development. D) Chemical structure of vaborbactam that is the first boron-based 𝛽-lactamase inhibitor approved by the food
and drug administration (FDA) and general structure of 1,6-diazabicyclo[3.2.1]octane (DBO) inhibitors. The combination therapy and the development
state are indicated in brackets.
𝛽-lactam antibiotics (penicillins, cephalosporins, monobactams,
and carbapenems), which compromise 70% of all antibacterial
drugs in clinical use.[21–23] These life-saving drugs are safe, very
effective, and well tolerated by most patients, with only few
cases of allergic reactions.[24] The mechanism of action involves
inhibition of the growth of the bacterial wall, specifically the
biosynthesis of the peptidoglycan catalyzed by PBPs (penicillin-
binding proteins), which imparts rigidity to this essential
structure for bacterial survival.[25] The alteration of the natural
balance between the synthesis of peptidoglycan and its hydroly-
sis, which is catalyzed by murein hydrolases, in the regeneration
of the bacterial wall is responsible for the bactericidal effect.
The utility of 𝛽-lactam antibiotics is being threatened by the
ever-increasing production and dissemination worldwide of
𝛽-lactamases.[26,27] These enzymes confer resistance to 𝛽-lactam
antibiotics through hydrolysis of the 𝛽-lactam ring to afford inac-
tive products, thus preventing the inhibition of their therapeutic
target, i.e., PBPs (Figure 1A). This inactivation process is one of
the most relevant resistance mechanisms in Gram-negative bac-
teria, including the multidrug-resistant pathogens highlighted
by the WHO, namely, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Entereobacteriaceae (Figure 1B).[28] Among the
different types of 𝛽-lactamase inhibitors, significant effort is cur-
rently being devoted to the development of compounds with an
ultrabroad-spectrum activity, i.e., activity against the four types of
𝛽-lactamase enzymes, which are characterized as having quite
distinct hydrolytic capabilities. This goal has proven to be
challenging given the variety of structural topologies of these
enzymes and themarkedly different mechanisms of action of the
serine-based enzymes when compared with the zinc-dependent
hydrolases. In particular, the search for efficient inhibitors
against the metallo-dependent enzymes, for which effective ther-
apies in clinical practice are currently not available, is one of the
field’s biggest unmet needs. The search for ultrabroad-spectrum
inhibitors that are able to inhibit serine- and metallo-𝛽-lactamase
enzymes is an emerging area in antibacterial drug discovery.
The present article is focused on the therapeutic potential of
recently developed combination therapies in which the latest
bicyclic boronates (monoester form) are used, specifically tani-
borbactam (formerly VNRX-5133, 1), the orally bioavailable in-
hibitor VNRX-7145 (2) and QPX7728 (3), which are in advanced
clinical development (Figure 1C). These resistance breakers are
the present hope against 𝛽-lactamase-producing carbapenem-
resistant superbugs that produce either serine- or/and metallo-
𝛽-lactamase enzymes. In order to gain an insight into the scope
of the bicyclic boronates currently under clinical study, this article
also provides a brief overview of the susceptibility spectrumof the
most recent combination therapies approved by the FDA involv-
ing other types of 𝛽-lactamase inhibitors, such as vaborbactam
and 1,6-diazabicyclo[3.2.1]octanes (DBOs) (Figure 1D). Finally,
the molecular basis of the ultrabroad-spectrum efficacy of tani-
borbactam and QPX7728 is also discussed based on the available
crystal structures of the enzyme complexes and the Molecular
Dynamics (MD) simulation studies discussed here.
2. 𝜷-Lactamases: Classes and Mechanisms
The overuse and misuse of 𝛽-lactam antibiotics over the last 80
years, together with the intrinsic evolutionary character of bac-
teria as a response to exposure to hostile environments, has led
to the development of a huge number of 𝛽-lactamase enzymes.
According to the Beta-lactamase database, ≈5000 𝛽-lactamases
have been identified to date and these are classified into four
groups (A–D) based on their sequence identities.[29–32] These en-
zymes have quite distinct hydrolytic capabilities and are struc-
turally diverse, with the most frequent classes being A (≈32%)
and C (≈30%), followed by D (≈20%), and B (≈14%).[29]
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Figure 2. Enzymatic hydrolysis of carbapenems catalyzed by A) serine-𝛽-lactamases and B) metallo-𝛽-lactamases. R = carbapenem side chain.
Classes A, C, and D are serine-𝛽-lactamase enzymes that hy-
drolyze the 𝛽-lactam antibiotic in a covalent-catalyzed process
that involves the formation of an acyl-enzyme adduct using a cat-
alytic serine residue, which behaves as the reactive nucleophile,
and an active site residue that acts as a general base (lysine, car-
boxylated lysine or glutamate) (Figure 2A).[33,34] The mechanism
involves two steps. i) The formation of a tetrahedral transition
state 1 TTS1 that will be stabilized by strong hydrogen bonding
interactions with the bottom part of the active site (the oxyanion
hole). ii) The deacylation process by hydrolysis of the acyl-enzyme
adduct through the formation of the tetrahedral transition state
2 TTS2.
Although the mechanism of action of the three types of
serine-𝛽-lactamases is globally similar, the structural differ-
ences between these species are very relevant and explain
their quite distinct hydrolytic capabilities and substrate pref-
erences. Thus, class A enzymes show quite diverse activity
since, even though they typically hydrolyze penicillins (in
fact they are historically known as penicillinases), some of
their variant enzymes have evolved to hydrolyze narrow- and
expanded-spectrum cephalosporins (SHV-2, TEM-10, CTX-M,
GES-1) and others even hydrolyze carbapenems (KPC, SME,
IMI, NMC-A, GES-2).[35,36] Class C enzymes mainly hydrolyze
cephalosporins (AmpC, CMY, ACT-1, DHA, FOX). The most
relevant examples of this group are the chromosomally encoded
AmpC enzymes that inactivate most cephalosporins, including
expanded spectrum cephalosporins (ceftazidime, cefotaxime,
ceftriazone) and cephamycins (cefoxitin). Although the basal
expression of AmpC-type enzymes is usually low, in most clin-
ical isolates high levels can be induced by exposure to 𝛽-lactam
antibiotics and/or by constitutive expression.[37] The AmpC-type
enzymes make the bacterium intrinsically resistant to most
cephalosporins. For P. aeruginosa, AmpC enzymes are known
as PDC (Pseudomonas-derived cephalosporinase) and these can
be induced in most clinical isolates by 𝛽-lactam antibiotics.[38]
Class D enzymes (oxacillinases, OXA) hydrolyze penicillins and
cloxacillin. However, OXA-type enzymes have also evolved to
inactivate narrow-spectrum cephalosporins (OXA-1, OXA-10),
expanded-spectrum cephalosporins (OXA-13, OXA-17) or even
carbapenems (OXA-23, OXA-24/40, OXA-48), which are known
as carbapenem-hydrolyzing class D 𝛽-lactamases.[31,39–47]
Unlike serine-𝛽-lactamases (A, C, and D), class B enzymes
inactivate 𝛽-lactam antibiotics through a completely distinct
mechanism that does not involve the formation of ligand-
enzyme adducts (Figure 2B). Instead, these enzymes catalyze
the hydrolysis of the 𝛽-lactam bond using a hydroxide anion as
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Figure 3. Close view of the active site observed in X-ray crystal structures of 𝛽-lactamases of subclasses B1, B2, and B3. Structures of VIM-1 from P.
aeruginosa (PDB 5N5G), CphA from Aeromonas hydrophyla (PDB 1×8G) and L1 Stenotrophomonas maltophilia (PDB 1SML) in the wild-type forms are
shown. Note how B1 and B3 subclasses are di-zinc-dependent enzymes that have a hydroxide anion bridging the two cationic centers and a common
Zn1 site arrangement (His-His-His triad). By contrast, only one catalytic Zn2+ ion is involved in the B2 subclass. A carbonate ion coordinated to the
metal is observed in PDB 1×8G.
a nucleophile (noncovalent catalysis).[48–56] Class B enzymes are
divided into three subclasses (B1, B2, and B3) based on primary
amino acid sequence homology, which is relatively low between
subclasses (<20%) but significantly higher within a subclass.
The B1 and B3 subclasses, which are the most abundant of the
three, exhibit a broad-spectrum activity as they can hydrolyze
penicillins, cephalosporins, and carbapenems. All B1 and most
of B3 enzymes are di-zinc-dependent hydrolases. By contrast,
the B2 enzymes are mono-zinc-dependent hydrolases that
specifically hydrolyze carbapenems and display poor hydrolytic
capacity against penicillins and cephalosporins. For the dinu-
clear enzymes (B1 and B3 subclasses), the hydroxide anion is
bridged by the two Zn2+ ions, which are in close proximity to one
another (Figure 3). One Zn2+ ion is coordinated to three histidine
residues (Zn1 site, tetrahedral) and the other ion is bound to a
water molecule and three residues (for B1 subclass, Asp-Cys-His;
and for B3 subclass, Asp-His-His) (Zn2 site, bipyrimidal). It has
been proposed that the 𝛽-lactam antibiotic hydrolysis process
is initiated by coordination of its carboxylate group to the Zn2
site and of its carbonyl group to the Zn1 site. This coordination
triggers the nucleophilic attack of the hydroxyl group located be-
tween the two ions, thus leading to the tetrahedral transition state
3 TTS3 and the cleavage of the C─Nbond (Figure 2B). An anionic
intermediate is then generated and subsequently protonated to
afford an enzyme/product complex before product release.[57]
Based on X-ray crystal structures of NDM-1 in complex with hy-
drolyzed imipenem andmeropenem, as well as NMRmonitoring
of the reaction process, significant differences in the hydrolysis of
carbapenems catalyzed by metallo-𝛽-lactamases were identified
compared with penicillins and cephalosporins.[58] The structures
of two NDM-1/intermediate complexes (PDBs 5YPK and 5YPI)
and the NDM-1/product complex (PDB 5YPL) captured revealed
that, in contrast to penicillin and cephalosphorin hydrolysis
(PDBs 4EYB and 4EYF),[55] the carbapenem hydrolysis mecha-
nism would involve intermediate complex lacking of a bridging
water molecule between the two Zn(II) centers. The final proto-
nation of the hydrolyzed carbapenem intermediate would take
place by reaction with a bulky water molecule located in the
𝛽-face.
Among the three subclasses, the B1 enzymes are the most
abundant and these include the clinically relevant and transfer-
able IMP-, VIM-, and NDM-type enzymes. These hydrolases are
themost directly related to 𝛽-lactam antibiotic resistance because
they are widely found in the deadly pathogens A. baumannii, P.
aeruginosa, andEnterobacteriaceae.[59,60] The B2 enzymes are chro-
mosomally encoded and characterized by a bipyramidal coordi-
nation of the catalytic Zn2+ ion as the Zn2 site arrangement.[48,61]
In this case, the nucleophilic hydroxide anionwould be generated
by deprotonation of the bridging water molecule between the as-
partate residue of the zinc coordination sphere and a histidine
residue in the vicinity (Asp120 and His118, respectively, in PDB
1×8G, Figure 3).[62] It has been suggested that one of the latter
two residues might act as a general base. The B2 subclass en-
zymes are inhibited when a second Zn2+ ion binds to the Zn1
site.[63] CphA and Sfh-I are the most relevant examples of this
enzyme subclass.
3. Carbapenemases: The Nightmare of
Anti-Infective Therapies Based on 𝜷-Lactam
Antibiotics
Despite being the least common 𝛽-lactamases in deadly
pathogens, class B enzymes represent a huge risk to hospital-
ized patients because i) they can potentially confer extremely
broad-spectrum resistance to antibiotics as—with the exception
of monobactams—they can hydrolyze virtually all 𝛽-lactam an-
tibiotics, and ii) clinically approved inhibitors are not currently
available. In addition, the extensive knowledge achieved over
the years on the inhibition of serine-𝛽-lactamases, which will
be briefly summarized in Section 4, is of little relevance in the
search for new inhibitors against these zinc-dependent hydro-
lases. Thus, there are marked differences between these two
types of enzymes, both in themechanism of action and the struc-
tural topology, which hinders the development of effective in-
hibitors based on previous scaffolds.[60,64–66]
Nowadays, there is a great deal of concern about the impact
of the infections caused by carbapenem-resistant A. baumannii,
P. aeruginosa, and Enterobacteriaceae that are frequently found
in hospitalized patients fitted with invasive devices or exposed
to extended antibiotic regimens.[67–70] Of particular concern is
the global incidence of class A carbapenemases, such as KPC,
SME, IMI, NMC-A, and GES-2, carbapenem-hydrolyzing class
D 𝛽-lactamases, such as OXA-23, OXA-24/40, and OXA-48,
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Figure 4. Most relevant carbapenemases widely found in multidrug-resistant pathogens A. baumannii, P. aeruginosa, and Enterobacteriaceae.
as well as metallo-𝛽-lactamases such as IMP, VIM, and NDM
(Figure 4). The ever-increasing appearance and dissemination
in clinical settings of these types of strains, which are mostly
encoded by plasmids, is worrisome since it significantly narrows
the therapeutic options and, in some cases, solutions are not
available. This issue is further exacerbated by the existence and
spread of bacterial strains that coproduce serine- and metallo-
carbapenemases. Thus, i) class B enzymes hydrolyze approved
serine-𝛽-lactamase inhibitors such as avibactam, and efficient
inhibitors against them are not clinically available,[71] and ii)
numerous examples of clinical isolates of Klebsiella pneumoniae
strains that coexpress NDM-1 and OXA-type enzymes have
already been found worldwide (India, Nepal, Italy, Korea, United
Arab Emirates, Switzerland).[72–79] It is therefore not surprising
that the development of carbapenemase inhibitors with an
ultrabroad-spectrum activity, i.e., effective against both metallo-
and serine-𝛽-lactamases, has become a flourishing research area
in drug discovery in recent years.
4. Overview and Spectrum Susceptibility of
Non-Boron-Based 𝜷-Lactamase Inhibitors
Themost relevant 𝛽-lactamase inhibitors, either in clinical use or
at different stages of development, are summarized in Figure 5.
Clavulanic acid (4) and the penicillin-based sulfones sulbactam
(5) and tazobactam (6), which were the first to be introduced in
clinic in combination with various penicillins (amoxicillin, ampi-
cillin, piperacillin, ticarcillin) as well as more recently with fourth
and fifth generation cephalosporins (cefepime, ceftolozane) are
only effective against bacterial strains that harbor extended-
spectrum-𝛽-lactamases (ESBLs, class A).[80,81] None of these com-
binations, including the recently developed enmetazobactam (7,
formerly AAI101)/cefepime,[82] are useful against strains that
produce the most relevant serine- and metallo-carbapenemases
or against class C cephalosporinases (Figure 4).
A huge breakthrough in 𝛽-lactamase inhibition was the devel-
opment of 1,6-diazabicyclo[3.2.1]octanes (DBOs) that was trig-
gered by the identification of its parent inhibitor, avibactam
(8), which was approved in 2014 by the FDA in combination
with ceftazidime.[83–85] Avibactam efficiently restores the bacte-
ricidal activity of ceftazidime against infections caused by bac-
terial strains producing class A carbapenemases (KPC-type),
class C cephalosporinases (AmpC-type), as well as some class
D enzymes (OXA-48) (Table 1). Unfortunately, the combination
avibactam/ceftazidime is ineffective against relevant strains har-
boring carbapenem-hydrolyzing class D 𝛽-lactamases, such as
OXA-23 and OXA-24/40, which are widely found in P. aerugi-
nosa and A. baumannii, as well as Enterobacteriaceae-producing
metallo-carbapenemases, such as NDM-1, IMP-1 and VIM-
1/VIM-2. Recently, avibactam in combination with aztreonam
and metronidazol has opened new therapeutic opportunities for
the treatment of infections caused byGram-negative bacteria pro-
ducing metallo-𝛽-lactamases, in particular, intra-abdominal in-
fections and nosocomial pneumonia.[86–87] This therapy, which
exploits the stability of aztreonam against class B enzymes and
is currently under phase III of clinical development, is efficient
against the vast majority of Enterobacteriaceae and particularly
attractive for patients with a history of allergy to other 𝛽-lactam
antibiotics. However, this treatment is not suitable for infections
caused by Gram-positive or anaerobic bacteria, since aztreonam
is inefficient against them.[88]
The discovery of avibactam (9) triggered a frantic race to ex-
pand its spectrum of activity by modification of its DBO scaf-
fold. In particular, significant attention has been devoted to ex-
pand avibactam’s activity against bacterial strains that express
class D carbapenemase OXA-23 and OXA-24/40 enzymes. Ef-
forts were initially focused onmodifications of the side chain (pri-
mary amide group), either directed to introduce into the scaffold
extra binding interactions with the active site and/or to improve
their pharmacological properties. This research led to the discov-
ery of relebactam (10), which was approved in 2019 by the FDA
in combination with imipenem and cilastatin,[89,90] followed by
zidebactam (11, formerly WCK 5222)[91–93] and nacubactam (12,
formerly RG6080, OP0595),[94–96] which are both under phase I
clinical studies in combination with cefepime and meropenem,
respectively. Unlike the other DBO inhibitors, nacubactam has
a dual mode of action because, in addition to being a serine-𝛽-
lactamase inhibitor, it also has bactericidal activity by targeting
PBP2 in Enterobacteriaceae.[96–98]
The most meaningful progress in the development of DBO
inhibitors occurred with the rigidification and functionalization
of the six-membered ring. This type of modification provided a
solution to one of the field’s long-pursued unmet needs, namely
to expand the inhibitory range of these compounds to include
class D 𝛽-lactamases, such as OXA-23 and OXA-24/40, in the
list of serine 𝛽-lactamases that can be blocked (Table 1). Unlike
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Figure 5. Clavulanic acid (5), most relevant examples of penicillin-based sulfones and 1,6-diazabicyclo[3.2.1]octanes. The combination therapy and
the development state are indicated in brackets. The chemical modifications in the parent inhibitors, sulbactam and avibactam, that have resulted in
subsequent analogs are highlighted in blue.
other 𝛽-lactamases, the latter class D carbapenemases have a
rigid and apolar tunnel-like entrance, which is composed of
a methionine and a tyrosine or phenylalanine residue, that
facilitates exquisite control of the substrate conformation for the
serine-catalyzed hydrolysis, thus enhancing the carbapenemase
activity.[99] The most prominent inhibitor, which was developed
by Entasis Therapeutics, is durlobactam (13, formerly ETX2514)
and together with sulbactam (5) this proved to be an excellent
therapeutic candidate for the treatment of infections caused by
multidrug-resistant Acinetobacter spp.[100–102] The combination
durlobactam/sulbactam is currently under phase III clinical
studies. The same company also developed ETX0282 (14), an
oral prodrug of another relevant DBO analog ETX1317 (15),
which is a regioisomer of durlobactam (13) in which the sul-
fate moiety has been replaced by an (R)-2-fluoroacetate group.
ETX0282 (14) in combination with cefpodoxime proxetil, which
is a prodrug of cefpodoxime approved for the treatment of
antibiotic-resistant Enterobacteriaceae urinary tract infection,
is a promising oral therapy for infections caused by ESBL-
producing and carbapenem-resistant Enterobacteriaceae.[103–106]
Undoubtedly, the broad-spectrum of activity of durlobactam (13)
and ETX0282 (14)—or its active form ETX1317 (15)—represents
a huge advance in restoring the efficacy of carbapenems in
infections caused by the WHO priority pathogens. However,
like avibactam these compounds are also inefficient against
metallo-𝛽-lactamases (Table 1).
5. Bicyclic Boronates: The Present Hope Toward
“Pan-𝜷-Lactamase Inhibitors”
In general, the ability of boronic acids to change their hybridiza-
tion state between sp2 (trigonal) and sp3 (tetrahedral) forms
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Table 1. Spectrum of activity of DBO inhibitors among the fourth classes
of 𝛽-lactamase enzymes.
Inhibitor Class A Class C Class B Class D
Avibactam (9) Yes Yes No Some
ESBL, KPC AmpC-type – OXA-10, OXA-48
Relebactam (10) Yes Yes No No
ESBL, KPC AmpC-type – –
Zidebactam (11) Yes Yes No No
ESBL, KPC AmpC-type – –
Nacubactam (12) Yes Yes No No
ESBL, KPC AmpC-type – –
Durlobactam (13) Yes Yes No Yes
ESBL, KPC AmpC-type – OXA-1, OXA-10, OXA-23,
OXA-24/40, OXA-48
ETX0282 (14) Yes Yes No Yes
ESBL, KPC AmpC-type – OXA-1, OXA-10, OXA-23,
OXA-24/40, OXA-48
in aqueous environments makes them good mimetics of the
transition state for enzymes using amides, esters or lactams as
substrates.[107] This feature and the improved pharmacokinetics
profile of the corresponding derivatives are attractive properties
that have been exploited in drug development and resulted in
several approved drugs. Good examples are bortezomid (Velcade,
FDA approved in 2005)[108] and ixazomid (Ninlaro, FDA approved
in 2015),[109] which are proteasome inhibitors used for the treat-
ment of myeloma, and tavaborole (Kerydin, FDA approved in
2014),[110] which is a Leucyl-tRNA synthetase inhibitor employed
for the treatment of onychomycosis (a fungal infection).
The investigations into the potential of boronic acids in the
𝛽-lactamase inhibition field emerged after it was demonstrated
that boric acid and subsequent diverse phenylboronic acids
inhibit serine-𝛽-lactamase enzymes.[33,111–113] These compounds
are considered good transition state analogs of TTS1 and
TTS2, for which their capacity to be in equilibrium between
their sp2/sp3 forms is also crucial to maximize their affinity
during both the binding and inhibition processes (Figure 2).
Thus, in the Michaelis complex formation step the sp2 form,
which usually predominates at neutral pH,[112] can mimic the
carbonyl group of 𝛽-lactam antibiotics as they also have an
sp2 geometry.[33] Once this complex is established, the ability
of the boronic acid to tune to the sp3 form provides a good
mimetic of the high-energy tetrahedral transition states TTS1
and TTS2 in the serine-𝛽-lactamase mechanism, as well as TTS3
in the conversion catalyzed by the metallo-𝛽-lactamase enzymes
(Figure 2). This effective “sp2/sp3 equilibrium process” is
consistent with the high kon and low koff values experimentally
observed in compounds of these types.[114,115]
Initially, the main bottleneck for the use of boronic acids in
this field was their potential side effects due to the additional in-
hibition of mammalian serine proteases.[116] However, the intro-
duction of cyclic boronates (1,2-oxaborinan-2-ol and 3,4-dihydro-
2H-benzo[e][1,2]oxaborinin-2-ol) was a turning point in the field
due to their greater selectivity against 𝛽-lactamase enzymes
(Figure 6). The latter characteristic is mainly caused by the re-
stricted conformation of this chemical scaffold, which would not
fit in the smaller active sites of the serine proteases as they have
been exquisitely designed for transforming more flexible sub-
strates. As for the penicillin-based sulfone inhibitors [sulbactam
(6), tazobactam (7), enmetazobactam (8)], the presence in the
scaffold of a carboxylate group in the 𝛼-position to the cyclic oxy-
gen atom proved to be pivotal for anchoring to the active site
of the serine-𝛽-lactamase enzymes, either through electrostatic
and/or hydrogen bonding interactions with key polar residues,
as well as for coordination to the Zn2+ ion of the metallo-𝛽-
lactamases.
5.1. Taniborbactam (VNRX-5133)
The inspiration for the design of inhibitors based on cyclic
boronates arose from the X-ray structure of TEM-1 𝛽-lactamase
from Escherichia coli covalently modified by (1R)-1-acetamido-
2-(3-carboxy-2-hydroxyphenyl)ethylboronic acid (PDB 1ERQ, 1.9
Å) reported by Ness et al. (Figure 6A).[117] In the structure, the
strong hydrogen bonding interaction observed between the phe-
nol group in the modified ligand and the oxygen atom of the cat-
alytic serine seems to induce a suitable arrangement of the ligand
for coordination to the catalytic Zn2+ ion through its phenol and
carboxylate moieties. This hypothesis led Burns et al.[118] in 2010
at Protez pharmaceuticals, a subsidiary of Novartis, to develop the
first boron-based compounds, specifically the bicyclic boronates,
that were able to inhibit both serine- and metallo-𝛽-lactamase en-
zyme. Further development at Venatorx Pharmaceuticals, with
particular attention paid to the optimization of the flexible side
chain of the ligand, led to the discovery of taniborbactam (1, for-
merly VNRX-5133), an injectable pan-𝛽-lactamase inhibitor (Fig-
ure 1C).[119–122] In parallel, Rempex Pharmaceuticals developed
diverse monocyclic boronates that allowed the identification of
vaborbactam (4, formerly RPX7009), which is the first boron-
based 𝛽-lactamase inhibitor approved by the FDA in combination
with meropenem (2017, vabomere) for the treatment of compli-
cated urinary tract infections (Figure 1D).[123,124] The European
Medicines Agency also approved the vaborbactam/meropenem
combination for the treatment of intra-abdominal infections and
hospital-acquired pneumonia.[125]
The most remarkable feature of varborbactam is its strong ca-
pacity in restoring the activity of carbapenems against strains
that produce ESBLs, especially KPC-producing Enterobacteri-
aceae, with Ki values in the nanomolar range (Table 2).
[123] This
compound provides highly stable adducts, the tridimensional
structure of which was solved by X-ray crystallography (PDB
6TD0,[126] 0.99 Å). Vaborbactam is a reversible inhibitor with
a remarkable very slow off-rate constant (≈40 µs−1) and a cor-
responding residence time of ≈7 h against KPC-enzymes.[127]
A substantially faster release of the vaborbactam bound form
occurs against other serine-𝛽-lactamases. In vitro studies with
KPC-producing strains showed that vaborbactam reduces the
minimum inhibitory concentration (MIC) values of meropenem
by ≥64-fold. This compound also efficiently inhibits other 𝛽-
lactamases of classes A (CTX-M, SHV, TEM-10) and C (Enter-
obacter cloacae cephalosporinase P99, K. pneumoniae CMY-2) in
the 10 × 10−9–100 × 10−9 m range but it does not have bac-
tericidal activity (Table 2).[128] Unfortunately, vaborbactam lacks
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Figure 6. The sp3 form of cyclic boronates is key for the inhibition of both serine andmetallo-𝛽-lactamases. A) sp2/sp3 equilibrium forms of 3,4-dihydro-
2H-benzo[e][1,2]oxaborinin-2-ol derivatives and schematic representation of the resulting serine adduct I and di-zinc-complex II. B) Detailed view of the
active site of 𝛽-lactamase TEM-1 from E. coli covalently modified by (1R)-1-acetamido-2-(3-carboxy-2-hydroxyphenyl)ethylboronic acid (PDB 1ERQ,[117]
1.9 Å). Note how the phenol group is in close contact with the catalytic Ser70 (2.3 Å). C) Tridimensional structure of I and II observed in PDB 6RTN[130]
(OXA-10 from P. aeruginosa) and 6SP7[131] (VIM-2 from P. aeruginosa). Only the bicyclic boronate core of the ligand (cyan) is shown.
clinical utility for the treatment of infections caused by bacterial
pathogens that produce carbapenemases of classes B and D, as
it proved to be a weak inhibitor of these enzymes (µM range).
Among the B1 subclass, its inhibitory activity against the IMP-1
enzyme stands out when compared to VIM-1/VIM-2 and NMD-
1, which are lower by a factor of around 5.
The bicyclic architecture of taniborbactam (1) has proven to be
key in achieving nanomolar activity against class B enzymes be-
cause of the conformational restraints induced by the fused aro-
matic ring that preorganizes the ligand for binding. This bicyclic
boronate efficiently inhibits the B1 subclass enzymes VIM and
NDM, with IC50 values in the nanomolar range, as well as serine-
𝛽-lactamases of ESBLs, OXA-type, and KPC-type (Table 2).[129–131]
This outstanding ultrabroad-spectrum activity makes tanibor-
bactam (1) an excellent antibiotic partner for the treatment of
infections due to carbapenem-resistant pathogens with dis-
tinct mechanisms of action, including carbapenem-resistant
Enterobacterales and carbapenem-resistant P. aeruginosa.[132]
Taniborbactam (1) is the first pan-𝛽-lactamase inhibitor to
enter clinical trials that is able to inhibit both metallo- and
serine-𝛽-lactamases. Specifically, in combination with cefepime,
a fourth-generation cephalosporin, it is currently in phase III
studies.
Venatorx Pharmaceuticals Inc. developed an orally bioavail-
able boron-based 𝛽-lactamase inhibitor, VNRX-7145 (2), which
is a proform of VNRX-5236, a bicyclic boronate derivative
structurally related to taniborbactam but with a short side chain
(propionamido).[133,134] In combination with ceftibuten, a third
generation cephalosporine, VNRX-5236 restores the antibiotic
efficacy against ESBLs and carbapenem-resistant Enterobac-
terales, including strains that harbor KPC-type and OXA-type
carbapenemases. The combination ceftibuten/VNRX-7145 is
currently in phase I clinical development.
Taniborbactam (1) is synthesized in six steps from commer-
cially available boronic acid 16 as shown in Scheme 1.[118–120] As
for the synthesis of other inhibitors based on cyclic boronates
such as vaniborbactam (4), Matteson’s reaction is employed for
the double homologation of the boronic acid pinanediol ester in-
termediate 17, which is readily prepared in two steps by double
esterification of 16 to give chloride 19. SN2 reaction of chloride 19
with lithium bis(trimethylsilyl)amide and subsequent coupling
with carboxylic acid 23 using HATU and NMO provide amide
20. The required acid 23 is prepared in five steps from commer-
cially available carboxylic acid 21. Finally, treatment of 20 with
BCl3 leads to the deprotection of all functional groups and the
formation of the bicyclic core in taniborbactam (1).
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Table 2. Inhibitory activity [IC50 (µm)] of taniborbactam (1), vaborbactam (4), avibactam (9), clavulanic acid (5), and tazobactam (7) against relevant
serine- and metallo-𝛽-lactamase enzymes.
Class Enzyme Taniborbactam (1) Vaborbactam (4) Avibactam (9) Clavulanic acid (5) Tazobactam (7)
A TEM-116 0.12[128] 6[128] NA
a ) NA NA
KPC-2 0.03[131] 0.09[128] 0.06[131] 1.8[131] 1.7[131]
SHV-5 0.0004[131] 0.44[131] 0.013[131] 0.012[131] 0.015[131]
CTX-M-15 0.01[131] 0.42[131] 0.003[131] 0.04[131] 0.001[131]
B1 IMP-1 39.8[131] 126[128] >100[131] >100[131] >100[131]
2.51[130]
NDM-1 0.19[131] 631[128] >100[131] >100[131] >100[131]
0.01[130]
VIM-1 0.0079[130] 398[128] NA NA NA
VIM-2 0.026[131] 316[128] >100[131] >100[131] >100[131]
0.0005[130]
B2 CphA 2.51[130] 631[128] NA NA NA
B3 L1 >10[130] 336[128] NA NA NA
C AmpC 0.301[130] 5[128] NA NA NA
P99 0.03[131] 0.09[131] 0.016[131] >100[131] 0.73[131]
CMY-2 0.007[131] 0.22[131] 0.007[131] >100[131] 0.41[131]
D OXA-1 0.16[131] 7.9[131] 0.04[131] 0.12[131] 0.43[131]
OXA-48 0.42[131] 25[128] 0.55[131] 30[131] 0.55[131]
0.54[130] 38.8[131] 0.55[131] 30[131] 0.55[131]
a)
NA = Not available.
Scheme 1. Synthesis of taniborbactam (1). Reagents, and conditions: (a) Isobutene, H2SO4 (c), dioxane, RT. (b) (+)-pinanediol, THF, RT. (c) CH2ClI,
nBuLi, THF, −100 °C to RT., CH2Cl2, −78 °C. (d) 1. CH2Cl2, nBuLi, THF, −100 °C. 2. ZnCl2, −100 °C to −10 °C. (e) 1. LHMDS, THF, −20 °C to RT. 2.
23, HATU, NMO, N,N-dimethylacetamide, RT. (f) BCl3, CH2Cl2, −78 °C. (g) BnBr, K2CO3, DMF, RT. (h) CH2Cl2, HCl (4 m in dioxane), RT. (i) 1. Et3N,
(CH2Cl)2, RT. 2. HOAc, N-Boc-aminoacetaldehyde, NaBH(OAc)3, RT. (j) 1. Boc2O, Et3N, CH2Cl2, RT. 2. H2 (g), Pd/C (10%), EtOAc, RT.
5.1.1. Molecular Basis of Taniborbactam’s Efficacy against Class B1
Metallo-𝛽-Lactamases
A differentiating feature between taniborbactam (1) and vabor-
bactam (4), beyond the markedly superior inhibitory capacity of
the former against class B enzymes (nanomolar vs micromo-
lar, respectively), is their distinct selectivity between B1 enzymes
(Table 2). Thus, while vaborbactam has a modest and similar in-
hibition of themain B1 enzymes (VIM-1/2, NDM-1, IMP-1), tani-
borbactam is notably more effective against VIM-1/2 and NDM-1
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Figure 7. Analysis of the available crystal structures of the B1 enzymes in complex with taniborbactam. A) Crystal structure of NDM-1 from K. pneumoniae
in complex with taniborbactam (PDB 6RMF,[130] 1.51 Å, chain A). Part of the ligand side chain is not shown since it has not been solved. Two types
of enzyme complexes are observed, specifically the bicyclic (I) and the tricyclic (II) boronate complexes. Form I is shown. B,D) Close view of the main
hydrophobic contacts between the bicyclic moiety in taniborbactam and the neighboring L3 loop residues (shown as spheres) of NDM-1 (B, Met67 and
Trp93) and VIM-2 (D, Phe61 and Trp87). C) Crystal structure of the VIM-2 from P. aeruginosa in complex with taniborbactam (PDB 6SP7,[131] 1.80 Å).
Relevant side chain residues are shown and labeled. Zn2+ ions are shown as spheres.
enzymes. Taniborbactam is around 7- and 1500-fold more potent
against VIM-1/2 than NMD-1 and IMP-1, respectively. By con-
trast, the activity of vaborbactam against the IMP-1 enzyme is
about 2.5- and 5-fold higher than for VIM-1/2 and NDM-1 en-
zymes, respectively.
Analysis of the available crystal structures of the B1 enzymes
in complex with taniborbactam reveals important structural dif-
ferences between them, specifically concerning the hydrophobic
pocket that surrounds the bicyclic moiety of the ligand—a dif-
ference that might explain these findings (Figure 7). The crystal
structures of the NDM-1 and VIM-2 enzymes in complex with
taniborbactam [PDB 6RMF[130] (1.51 Å) and 6SP7[131] (1.80 Å), re-
spectively] show that the ligand is anchored to the catalytic center
through coordination to: i) the Zn1 site via the boronate moiety;
and ii) the Zn2 site via the carboxylate group (Figures 7A,C). In
both structures the endocyclic oxygen atom in the ligand also in-
teracts with the Zn2 site. For the NDM-1/taniborbactam complex
two types of complexes are observed, namely, the bicyclic com-
plex I and the tricyclic complex II (Figure 7A). The latter complex
would result from the intramolecular nucleophilic addition of the
OH group of the boronate monoester form to the amide group of
the side chain. In both complexes the bicyclic ring of taniborbac-
tam is located on the apolar pocket involving the L3 loop and one
of the faces of the 𝛽2 and 𝛽3 sheets. The structural differences in
this hydrophobic pocket, as well as the dissimilar arrangement
of the L3 loop between the three enzymes, seem to be mainly re-
sponsible for the distinct inhibitory potency observed. Thus, for
the VIM-2/taniborbactam complex, the bicyclic moiety is deeply
surrounded by residues Phe61 and Trp87 to establish strong CH–
𝜋 interactions with them (Figure 7D). However, for the NDM-
1/taniborbactam complex, the position equivalent to Phe61 is oc-
cupied by Met67 (Figure 7B). Although the interactions between
aromatic rings and the sulfur atoms of the methionine residues
are relevant and are commonly found in numerous crystal struc-
tures, the bicyclic moiety is less efficiently beset by the enzyme,
which might account for its lower affinity against the NDM-1
enzyme.[135–137]
Moreover, the comparison of the crystal structures of IMP-
1 from S. marcescens (PDB 5EV6, 1.98 Å, wild-type form),[138]
NDM-1 fromK. pneumoniae (PDB 4EYL, 1.90 Å),[55] and the VIM-
2/taniborbactam complex reveals that the IMP-1 active site is
highly shielded by its L3 loop (Figure 8). This tunnel-like archi-
tecture of the IMP-1 active site, which is similar to the carbapen-
emases of class D OXA-23 and OXA-24/40, would make it diffi-
cult to achieve binding of rigid systems such as taniborbactam.
By contrast, the arrangement of the L3 loop as an active site lid,
which is observed in the VIM-2 enzyme, would facilitate the en-
trance of conformationally constrained ligands, and also promote
favorable contacts with them.
In order to gain further insights into these relevant struc-
tural differences, the binding modes of vaborbactam and tani-
borbactam in the active site of VIM-2 were modeled using the
Gaussian 09W[140] program package at density functional theory
(DFT) level by means of the B3LYP functional, and the enzyme
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Figure 8. Comparison of the L3 loop arrangement in diverse crystal structures of the B1 enzymes. A) Superposition of the crystal structures of NDM-
1/taniborbactam (green, PDB 6RMF[130]), VIM-2/taniborbactam (gray, PDB 6SP7[131]), and IMP-1 from S. marcescens (pink, PDB 5EV6[138]). B) Overall
view of the crystal structures of NDM-1 (PDB 4EYL[55]), IMP-1 (PDB 5EV6), and VIM-2 (PDB 4NQ2[139]). The L3 loop in all enzymes is highlighted in
red. Relevant side chain residues are shown. Zn2+ ions are shown as spheres.
Figure 9. Comparison of vaborbactam and taniborbactam binding mode to VIM-2. Proposed binding mode of A) vaborbactam and B) taniborbactam
in the active site of VIM-2 from P. aeruginosa obtained by molecular modeling. C) Comparison of (A) and (B). Relevant side chain residues are shown
and labeled. Relevant hydrogen bonding and hydrophobic interactions are shown as dashed lines (red and black, respectively). Note how taniborbactam
interacts by a strong hydrogen bonding interaction with the Asn233 side chain, which is located in the L10 loop, and also establishes more hydrophobic
contacts with Phe61, which is located in the L3 loop.
coordinates determined in PDB 6SP7.[141,142] The standard 6–
31G+(d,p)[143,144] basis set was used for C, H, O, S, B, and N, and
the LANL2DZ relativistic pseudopotential was used for Zn.[145]
The binding mode of taniborbactam with VIM-2 was also mod-
eled as a control to validate the methodology employed. The re-
sults with the VIM-2 enzyme showed that the introduction of a
fused aromatic ring in the cyclic boronate scaffold facilitated the
approach of the amide side chain to the L10 loop (Figure 9). As
a consequence, a strong hydrogen bonding interaction with the
Asn233 side chainwas established, whichwas not observed in the
VIM-2/vaborbactam enzyme complex (Figure 9A vs B). In addi-
tion, the aromatic ring in taniborbactam also enhanced the CH–𝜋
interactions with the residue Phe61 located on the L3 loop. For
the vaborbactam/VIM-2 complex, the latter contacts mainly in-
volve the methylene group of the six-membered ring. These two
extra interactions might be responsible for the markedly higher
affinity of taniborbactam against the VIM-2 enzyme.
Comparison of the available crystal structures of IMP-1,
VIM-1/2, and NDM-1 in the unbound form and in complex with
inhibitors, shows that the binding of the ligand causes: i) the dis-
tancing of both metal centers; and ii) that the latter effect is more
pronounced as there are several atoms of the ligand involved in
the coordination. Thus, for the unbound forms, the observed
range of distances between both Zn2+ ions are 3.3–3.6 Å for IMP-
1, 3.4–3.8 Å for VIM-1/2, and 3.4–3.8 Å for NDM-1 (Figure S1,
Supporting Information). In the latter case, only in few examples
distances of up to 4.2 Å are observed, which might be crystal-
lographic artifacts. As expected, similar values are observed for
those binary enzyme/ligand complexes where the hydroxyl group
bridging both ions is replaced by one atomof the ligand (thiolate).
However, for those enzyme/ligand complexes containing phos-
phates or cyclic boronates coordinated to the two Zn2+ ions, the
distance observed is significantly greater to accommodate more
atoms between them. Thus, for these cases, the commondistance
range between Zn2+ ions is 4.2–4.4 Å for VIM-1/2 and NDM-1
complexes. As a result of the distancing of both metal centers,
the loop that surrounds both ions (bottom part of the active
site), namely L10, display distinct arrangements to maximize the
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Figure 10. Analysis of the intrinsic shape-changing motions of IMP-1 and VIM-2 enzymes. A,B) RMSD plots for the protein backbone (C𝛼, C, N, and
O atoms) calculated per residue in the wild-type form of IMP-1 from Serratia marcescens (A, PDB 5EV6) and VIM-2 from P. aeruginosa (B, PDB 5ACU)
obtained from MD simulations studies. C,D) Superposition of several snapshots of the IMP-1 (C) and VIM-2 (D) enzymes during 100 ns of simulation.
The Zn2+ ions, the side chain residues that coordinate the two metal centers and the bridging hydroxide group are shown as small spheres and sticks.
L3 and L10 loops are highlighted with yellow shading. Note the limited flexibility of the L10 loop for the IMP-1 enzyme.
interactions with the ligand. For the IMP-1 enzyme, since there
are no crystal structures in complex with cyclic boronate in-
hibitors as well as phosphates, it is unclear if a similar behavior
might occur.
To get further insights into the induced-fit capacity of the
catalytic center of B1 enzymes, the intrinsic shape-changing
motions of these enzymes were analyzed by MD simulations.
These enzyme motions are essential for the catalysis/inhibition
(turnover) and are often modulated by ligand binding and might
explain the experimentally observed selectivity of the cyclic
boronate inhibitors against the B1 enzymes. These computa-
tional studies were performed on the unbound forms of IMP-1
and VIM-2 for 100 ns by using the enzyme coordinates of IMP-
1 from S. marcescens (PDB 5EV6, 1.98 Å)[138] and VIM-2 from P.
aeruginosa (PDB 5ACU, 2.10 Å)[146] (for further details see the Ex-
perimental Section). A truncated octahedron of water molecules
obtained with the molecular mechanics force field AMBER was
used to simulate the biological environment. The results of these
simulations clearly showed that while the L3 loop (lid) is very
flexible for both enzymes, for the L10 loop this is not the case
(Figure 10). Thus, for the VIM-2 enzyme, the L10 loop proved to
have large capacity to adopt ample and diverse arrangements to
host ligands of different sizes, geometries, and conformational
restrains. By contrast, for the IMP-1 enzyme, no significant mo-
tion of the L10 loop was observed during the whole simulation.
Specifically, a large opening of the L3 and L10 loops of up to
≈8 and ≈10 Å, respectively, takes place for the VIM-2 enzyme,
but for the IMP-1 enzyme only a significant opening of the L3
loop (≈10 Å) was observed. These clear differences and the lim-
ited plasticity of the L10 loop of the IMP-1 enzyme was also
corroborated by examination of the vibrational modes calculated
by principal-component analysis as implemented in AMBER
(Figure 11).
Taken together, these findings suggested that the IMP-1 en-
zyme has reduced induced-fit capacity for binding conforma-
tional restricted ligands such as cyclic boronate inhibitors, which
might explain the weak inhibition potency of vaborbactam and
taniborbactam (micromolar) against this enzyme. In addition,
the aforementioned structural differences, as well as dissimilar
arrangement of the L3 loop between the three enzymes, would
be responsible for the high affinity of taniborbactam for the VIM-
1/2 and NDM-1 enzymes.
Adv. Therap. 2021, 4, 2000246 2000246 (12 of 21) © 2021 The Authors. Advanced Therapeutics published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advtherap.com
Figure 11. Overall view of the motion of the L3 and L10 loops of A) IMP-1
and B) VIM-2 obtained by examination of the vibrational modes. The main
vibrational modes are presented.
5.2. QPX7728
Research efforts toward the development of ultrabroad-𝛽-
lactamase inhibitors have also been focused on exploring the
effects of the substitution of the aromatic core of the 3,4-dihydro-
2H-benzo[e][1,2]oxaborinin-2-ol scaffold. The ortho position to the
carboxylate group has been the most widely studied.[147–150] The
investigations carried out by researchers at Qpex Biopharma Inc.
showed that this type of substitution is important for i) avoiding
the formation of oligomers, which can be an issue at certain pHs
and concentrations, and ii) reducing the impact of the MexAB-
OprM efflux pump in bacterial strains of P. aeruginosa.[151] The
types of substituents explored in the aromatic ring (R group) are
summarized in Figure 12 along with the two types of side chains
(methylthioacetamide and 1,3,4-thiadiazolyl-2-thio groups) that
provided the most relevant inhibitors. Among the substituents
explored, small groups, such as methoxy and fluoro, provided
the best results. The initial studies led to the identification of
the methylthioacetamide derivative 24, which unfortunately
proved to inhibit only serine-𝛽-lactamases of classes A and
C. Subsequent studies allowed the identification of a more
promising compound, bicyclic boronate 25, that also proved
to be active against class B enzymes. Compound 25 contains
a 1,3,4-thiadiazolyl-2-thio-group in the 𝛼-position to the boron
center and a methoxy group as a substituent on the aromatic
core. Regretfully, as with taniborbactam, compounds 24 and 25
do not inhibit the worrisome carbapenemases of class D, such as
OXA-23.
Surprisingly, the removal of the substituent in the 𝛼-position
to the boron atom in the ortho-substituted derivative 25 pro-
vided an excellent ultrabroad-spectrum inhibitor, compound 26
(Figure 12B). Unlike derivative 25, inhibitor 26 displays remark-
able activity against the challenging carbapenemases of class D,
specifically OXA-23 and OXA-72, which are widespread in A.
baumannii.[147] In addition, compound 26 exhibits an improved
activity profile against enzymes of classes A and C, and, as with
compound 25, retains excellent activity against the metallo-𝛽-
lactamases VIM-2 and NDM-1, but its activity against IMP-26 is
worse than that of the parent compound.However, despite the ex-
cellent pharmacokinetic properties in rats, further development
of compound 26 was discontinued because subsequent in vivo
studies in dogs andmonkeys revealed the formation of long-lived
metabolites resulting from an oxidative deboronation process.
Subsequent investigations aimed at avoiding the latter process
by introducing small substituents in positions 3, 4 or both in 26
led to the discovery of QPX7728 (3), a metabolically stable, re-
markably potent and ultrabroad-spectrum inhibitor with poten-
tial for both intravenous and oral application.[127,147,152] QPX7728
in combination with QPX2014 (chemical structure not yet dis-
closed) is currently under phase I clinical trials.
QPX7728 (3) is synthesized in ten steps from commercially
available 2-bromo-5-fluorophenol (27) (Scheme 2).[148–150,153]
Firstly, treatment of phenol 27 with Boc2O and DMAP, followed
by deprotonation of the resulting carbonate 28 by reaction with
LDA to trigger the intramolecular migration of the vicinal car-
boxylate group, and reprotection of the resulting phenol gives
compound 29. Hydrolysis of the Boc and ester groups in 29 by
treatmentwith TFA and subsequent intramolecular esterification
by reaction with acetone in the presence of trific acid anhydride
and TFA provide ester 30. The required (Z)-vinylboronic acid
pinanediolato ester moiety for the introduction of the cyclopropyl
ring and formation of the bicyclic moiety in 3 is then achieved
in three steps involving i) Heck cross-coupling between bromide
30 and acrylic acid, using Pd(OAc)2 as catalyst and P(oTol)3, ii)
bromination of the resulting carboxylic acid 31 followed by de-
carboxylative elimination to afford the (Z)-bromovinyl deriva-
tive 32; and iii) Suzuki cross-coupling between bromide 32 and
bis[(+)-pinanediolato]diboron using PdCl2(dppf) as catalyst. The
palladium-catalyzed cyclopropanation of alkene 33 by treatment
with diazomethane gives the two possible diastereoisomers 34
and 35. Basic hydrolysis of the ester group and subsequent re-
moval of the (+)-pinanediol lead to QPX7728 (3).
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Figure 12. A) Examples of ortho-substituted bicyclic boronates explored. B) Chemical structures of the most relevant inhibitors identified and their scope
of activity.
Scheme 2. Synthesis of QPX7728 (3). Reagents, and conditions: (a) Boc2O, DMAP, CH2Cl2, RT. (b) LDA, THF, −78 °C to RT. (c) Boc2O, DMAP, CH2Cl2,
RT. (d) 1. TFA. 2. acetone, TFA, Tf2O, 65 °C. (e) Acrylic acid, Pd(OAc)2, P(oTol)3, Et3N, DMF, 100 °C. (f) Br2, CHCl3, 0 °C. (g) Et3N, DMF, 0 °C. (h)
bis[(+)-pinanediolato]diboron, PdCl2(dppf), KOAc, dioxane, 60 °C. (i) CH2N2, Pd(OAc)2, THF, −10 °C to RT. (j) 1. NaOH (3 m), dioxane, RT. 2. Et3SiH,
TFA, iBuB(OH)2, 0 °C.
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Table 3. IC50 (nm) values ofQPX7728 (3), vaborbactam (4), avibactam (9), and relebactam (10) against relevant serine- andmetallo-𝛽-lactamase enzymes.








A TEM-10 2.2 470 4.3 160
KPC-2 2.9 110 22 82
SHV-12 1.9 56 0.61 330
CTX-M-14 0.94 110 1.4 34
B1 IMP-1 610 >160 000 >160 000 >160 000
NDM-1 55 >160 000 >160 000 >160 000
VIM-1 14 >160 000 >160 000 >160 000
C P99 22 88 26 36
D OXA-23 1.2 120 000 3100 ND
c)
OXA-48 1.1 6900 180 90 000
a)
IC50 values were measured using imipenem as substrate;
b)
Data from ref. 154;
c)
ND = not determined.
Figure 13. Crystal structures of serine- and metallo-𝛽-lactamase enzymes in complex with QPX7728: A) KPC-2 from K. pneumoniae (PDB 6V1J[146]),
B) OXA-48 from K. pneumoniae (PDB 6V1O[147]), C) VIM-2 from P. aeruginosa (PDB 6V1P[147]), and D) NDM-1 from K. pneumoniae (PDB 6V1M[147]).
Relevant side chain residues are shown and labeled. Zn2+ ions are shown as spheres.
Biochemical assays showed that QPX7728 is a 𝛽-lactamase
inhibitor with a groundbreaking spectrum of activity, including
the most worrisome 𝛽-lactamases of the four classes. Thus,
QPX7728 efficiently inhibits ESBLs, including class A carbapen-
emases such as KPC, as well as class C cephalosporinases such
as P99, with IC50 values in the nanomolar range (Table 3).
[154]
The latter activity is comparable or better than those of other
𝛽-lactamase inhibitors in clinical use, such as avibactam, rele-
bactam or vaborbactam. The most remarkable improvement
for QPX7728 is against enzymes of metallo-𝛽-lactamases and
OXA-type enzymes. Thus, its inhibitory potency against class
B enzymes, such as VIM-1 (IC50 = 14 × 10−9 m) and NDM-1
(IC50 = 55 × 10−9 m), as well as class D carbapenemases such
as OXA-48 from K. pneumoniae (IC50 = 1.1 × 10−9 m) and
OXA-23 from A. baumannii (IC50 = 1.2 × 10−9 m) is outstanding
considering that the FDA approved inhibitors either show no
significant activity (class B) or are up to 2500-fold less active
(class D) against bacterial strains that express these hydrolases.
QPX7728 is also better than durlobactam (phase III), which
is efficient against OXA enzymes from A. baumannii but does
not inhibit class B enzymes.[102,103] In general, the inhibitory
profile of QPX7728 is also wider than the only clinically available
boron-based inhibitor vaborbactam, which is a weak inhibitor
of 𝛽-lactamases of classes B and D. Furthermore, its activity
against OXA carbapenemases from Acinetobacter spp. is also an
advantage over taniborbactam, the new boron-based inhibitor in
phase III clinical trials.[131] On the other hand, QPX7728 does
not inhibit mammalian serine and metalloproteases with the
exception of cathepsin A, whose activity is currently being
investigated further.
Microbiological studies with an extensive collection of bacte-
rial strains have demonstrated the excellent capacity of QPX7728
to restore the antibiotic efficacy of diverse 𝛽-lactam antibiotics,
either intravenously administered (ceftazidime, piperacillin,
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cefepime, ceftolozane, meropenem), or orally bioavailable
(ceftibuten, cefpodoxime, tebipenem).[153] Specifically, these
studies were performed with strains that express ESBLs (CTX-
M, SHV, TEM, VEB, PER), both plasmidic (CMY, FOX, MIR,
DHA) and chromosomally encoded (P99, PDC, ADC) class C
𝛽-lactamases, class A carbapenemases (KPC, SME, NMC-A,
BKC-1), class D carbapenemases (OXA-48, OXA-23, OXA-24/40,
OXA-58), and class B carbapenemases (NDM, VIM, CcrA, IMP,
and GIM). Moreover, susceptibility studies carried out on a large
collection of carbapenem-resistant Enterobacterales revealed that
the combination meropenem/QPX7728 has a very attractive
microbiological profile for infections caused by pathogens with
multiple resistance mechanisms.[155]
From the structural point of view, the main differences be-
tween taniborbactam (1) and QPX7728 (3) are i) the higher
overall rigidity of the latter due to the additional restraint caused
by the introduction of a cyclopropane ring in the 3,4-dihydro-
2H-benzo[e][1,2]oxaborinin-2-ol scaffold, and ii) the extra and/or
more potent contacts resulting from (a) the substitution with an
electron-withdrawing group (fluoro), and (b) the incorporation
of the cyclopropane moiety. Analysis of the available crystal
structures of KPC-2 from K. pneumoniae (PDB 6V1J,[147] 1.3 Å),
OXA-48 from K. pneumoniae (PDB 6V1O,[147] 1.8 Å), VIM-2
from P. aeruginosa (PDB 6V1P,[147] 1.2 Å), and NDM-1 from K.
pneumoniae (PDB 6V1M,[147] 1.05 Å) in complex with QPX7728,
revealed that option (ii) is more likely (Figure 13). Thus, in all of
the structures the cyclopropane ring is located in an apolar pocket
of the enzyme active site, and the aromatic ring is exquisitely
flanked by residues that can establish CH–𝜋 interactions with
this aromatic ring. The latter type of interaction is particularly
relevant considering the electron-deficiency of this aromatic ring,
which contains three electron-withdrawing substituents [F, CO2,
OB(OH)2].
[156] For instance, for the OXA-48/QPX7728 complex,
the cyclopropyl moiety is surrounded by residues Trp105 and
Val120, which are located close to the methylenic group, and the
aromatic ring establishes CH–𝜋 interactions with the side chains
of residues Tyr211, Ile102, and Leu247, which are flanking both
faces of the ring. This arrangement explains the much weaker
inhibitory potency of its enantiomer (3S,4R) (≈10-fold against
OXA-type enzymes), particularly for those enzymes that have
large apolar subpockets in the active site, such as OXA-48.[147]
6. Conclusion
The outstanding and ultrabroad-spectrum inhibitory capacity of
taniborbactam, VNRX-7145, and QPX7728 against challenging
𝛽-lactamase enzymes, which have been summarized here,
pinpoint bicyclic boronate inhibitors as the present hope against
multidrug-resistant bacteria. With these recently discovered
boron-based inhibitors a long-pursued unmet goal has been
achieved, namely to restore the efficacy of 𝛽-lactam antibiotics
against bacterial strains that produce metallo-𝛽-lactamases, for
which inhibitors in clinical use are not currently available. Even
more relevant is the fact that these inhibitors open the door to the
use of the same compound for therapies that involve bacterial
strains that coproduce both serine- and metallo-𝛽-lactamase
enzymes. Although the great structural diversity of these types
enzymes makes it challenging to find an excellent inhibitor for
all of them, QPX7728 seems to be the most universal of the
inhibitors produced to date. The future of this bicyclic boronate
inhibitor, which is currently under phase I clinical studies in
combination with QPX2014, looks exciting. It is important to as-
certain whether future combinations of QPX7728 with 𝛽-lactam
antibiotics in clinical use could enter clinical development. In any
case, the excellent structural information available and the results
already achieved augur well for a boom in research around the bi-
cyclic boronate scaffold in the near future. One can envisage that
this will eventually bring more effective therapeutic solutions for
dealing with one of the most serious challenges in global health.
7. Computational Methods
Molecular Modeling Studies: All calculations were performed by using
the Gaussian 09W[140] program package at DFT level by means of the
B3LYP functional.[141,142] The standard 6–31+G(d,p)[143,144] basis set was
used for C, H, O, S, B, and N, and the LANL2DZ relativistic pseudopoten-
tial was used for Zn.[145] The starting point of these calculations was taken
from crystallographic structures PDB 6SP7 (chain E) including the follow-
ing residues: Phe61, Trp87, His116, His118, Asp120, His196, CysS221,
Gly232, Asn233, His263, both Zn atoms (labeled as residues 301 and
302), Zn-bonded taniborbactam (residue 306 named K9B) and the water
molecule 441. All amino acids were truncated at C𝛼 positions with amethyl
group, except for Asn233, whose C𝛼 was transformed into a methylene
group keeping the nitrogen atom of the main chain and carbonyl group of
Gly232 (transformed into an acetyl group). Hydrogen atoms were added
to complete valences, considering all the histidine residues in the neutral
form, and protonated in 𝜖 position except His118 protonated in 𝛿 posi-
tion. Asp120 and Cys221 were used in the anionic form. The side chain of
taniborbactam was truncated into an acetyl amide group, the oxygen atom
O07 and the carboxylate group in the ligand were considered as hydroxyl
and carboxylate groups, respectively. Vaborbactam was manually modeled
from taniborbactam coordinates in a similar fashion. To represent better
the geometry in the enzyme active site, minimization of both systems was
performed while fixing the Cartesian coordinates for the C𝛼 and C𝛽 atoms
of all residues.
Molecular Dynamics Simulations Studies–Protein Preparation: The pro-
tein coordinates found in the crystal structure of IMP-1 from S. marcescens
(PDB 5EV6, 1.98 Å)[138] and VIM-2 from P. aeruginosa (PDB 5ACU, 2.10
Å),[146] both in the wild-type form, were used. For the IMP-1 enzyme, co-
ordinates from chain D were selected. Computation of the protonation
state of all titratable groups at pH 7.0 was carried out using the H++ Web
server.[157,158] As a result of this analysis His19 and His34 for IMP-1 and
His55,His170,His252,His285, andHis293 for VIM-2were protonated in 𝜖
position. Parameterization of the Zn-contained active site was carried out
as using MCPB module of AMBER Tools 17,[159,160] following the method
described in the AMBER tutorial 2.4.[161] Active site of both enzymes con-
sisted of the following residues: i) for coordination to Zn1 ion (residue
number 301/1296): His77/His116, His79/His118, and His139/His196 (in
IMP-1/VIM-2, respectively); ii) for coordination to Zn2 ion (residue num-
ber 302/1297): His197/His263, Asp81/Asp120, and Cys158/Cys221; and
a water molecule (residue number 400/1001) situated between both Zn2+
cations that was modeled as hydroxide. All histidine residues were con-
sidered in their neutral form and coordinated to the Zn atoms through
the nitrogen atom in 𝜖 position (NE2) except for His79/His118 that is
coordinated through the nitrogen atom in 𝛿 position (ND1). Residues
Asp81/Asp120 and Cys158/Cys221 both are bound in the anionic form
through the atoms OD2 and SG, respectively.
The bond and angle force constants for the active site residues were
determined from the sub matrices of the Cartesian Hessian matrix
calculated using Gaussian 09 using the Seminario Method.[162] Partial
charges for the active site residues were derived by quantum mechanical
calculations using Gaussian 09, according to the RESP[163] model.
Addition of hydrogen atoms and molecular mechanics parameters from
the ff14SB[163] force field were assigned to the proteins using the LEaP
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module of AMBER Tools 17. IMP-1 protein was immersed in a truncated
octahedron of ≈9100 TIP3P water molecules and neutralized by addition
of chloride ions. VIM-2 protein was immersed in a truncated octahedron of
≈6400 TIP3P water molecules and neutralized by addition of sodium ions.
Minimization of the Unbound Forms: The system was minimized in
four stages: a) initial minimization of the active site residues, hydroxide
and Zn ions (1000 steps, first half using steepest descent and the rest us-
ing conjugate gradient); b) minimization of the solvent and ions (5000
steps, first half using steepest descent and the rest using conjugate gra-
dient); c) minimization of the side chain residues, waters, and ions (5000
steps, first half using steepest descent and the rest using conjugate gradi-
ent); d) final minimization of the whole system (5000 steps, first half using
steepest descent, and the rest using conjugate gradient). A positional re-
straint force of 50 kcal mol−1 Å−2 was applied to the whole system except
the active site, the whole protein and 𝛼 carbons during the first three stages
(a–c), respectively.
Simulations of the Unbound Forms: MD simulations were performed
using the pmemd.cuda_SPFP[165–167] module from the AMBER 16 suite of
programs. Periodic boundary conditions were applied, and electrostatic in-
teractions were treated using the smooth particle mesh Ewaldmethod[168]
with a grid spacing of 1 Å. The cutoff distance for the nonbonded interac-
tions was 9 Å. The SHAKE algorithm[169] was applied to all bonds contain-
ing hydrogen using a tolerance of 10−5 Å and an integration step of 2.0 fs.
The minimized system was then heated at 300 K at 1 atm by increasing
the temperature from 0 to 300 K over 100 ps and by keeping the system
at 300 K another 100 ps. A positional restraint force of 50 kcal mol−1 Å−2
was applied to all 𝛼 carbons during the heating stage. Finally, an equilibra-
tion of the system at constant volume (200 ps with positional restraints
of 5 kcal mol−1 Å−2 to 𝛼 carbons) and constant pressure (another 100 ps
with positional restraints of 5 kcalmol−1 Å−2 to 𝛼 carbons) was performed.
The positional restraints were gradually reduced from 5 to 1 mol−1 Å−2
(5 steps, 100 ps each), and the resulting systems were allowed to equi-
librate further (100 ps) without restraints. Unrestrained MD simulations
were carried out for 100 ns. System coordinates were collected every 10 ps
for further analysis.
The molecular graphics program PyMOL[170] and CHIMERA[171] was
employed for visualization and depicting enzyme structures. The cpptraj
module in AMBER Tools 17 was used to analyze the trajectories and to
calculate the rmsd of the protein during the simulation.[172] The vibra-
tional modes for both metallo-𝛽-lactamases were calculated by principal
component analysis with the cpptraj module from the corresponding MD
trajectories.[173]
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